Lapatinib resistance is mostly due to the switch of survival signaling from HER2 to other signals, such as AXL RTK [29], Src family kinase [30], etc. Moreover, the mechanism underlying lapatinib resistance may be different in HER2-positive breast cancer cells with or without estrogen receptor (ER) [31, 32]. The gene discussed is AXL; the disease is breast cancer.